

## ASX Announcement

### Race to Present at the *Gold Coast Investment Showcase* & Hold Brisbane Investor Briefing

---

2 June 2025 – Race Oncology Limited (“Race”) is pleased to announce that Race CEO Dr Daniel Tillett will be presenting at the upcoming *Gold Coast Investment Showcase* on 25-26 June 2025.

Race also invites shareholders and interested investors to an in-person briefing to be held in Brisbane on Friday 27 June 2025.

#### Gold Coast Investment Showcase

The *Gold Coast Investment Showcase* is being held at the JW Marriott Gold Coast Resort & Spa on the 25-26 June 2025. Managing Director and CEO, Dr Daniel Tillett will present at 10.30am on Thursday, 26 June 2025. Dr Tillett will be available to meet attendees and discuss the latest company developments at the Race booth during the two days of the event.

For more information on the *Gold Coast Investment Showcase* and to register for the event, please visit: <https://www.goldcoastinvestmentshowcase.com.au>

#### Brisbane Investor Briefing

Race is pleased to invite shareholders and potential new investors to attend an in-person investor briefing and light morning tea in Brisbane on the 27 June 2025.

Executive Chairman, Dr Pete Smith and CEO, Dr Daniel Tillett will present an update before opening for a Q+A session from investors.

#### Event details

- Date:** Friday, 27 June 2025
- Time:** 10:15am for a 10:30am start and a 12:00pm finish
- Location:** Workspace 365  
Level 4, 260 Queen St  
Brisbane, QLD
- Format:** Morning tea and an investor briefing with live Q+A
- RSVP:** By Monday 16 June to: [anna.cvijetic@irdepartment.com.au](mailto:anna.cvijetic@irdepartment.com.au)

The Race team looks forward to seeing all those who can join us at either or both events.

-ENDS-

## About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule anticancer drug. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect with less cardiotoxicity compared to anthracyclines such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anticancer activity in solid tumours. Race is also exploring RC220 as a low-intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m<sup>6</sup>A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m<sup>6</sup>A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at [www.raceoncology.com](http://www.raceoncology.com).

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

*Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at [www.automicgroup.com.au](http://www.automicgroup.com.au).*

### Release authorised by:

Daniel Tillett, CEO  
info@raceoncology.com

### Media contact:

Jane Lowe +61 411 117 774  
jane.lowe@irdepartment.com.au